Pancreatic cancer and clinical trials
David H. Henry, MD, host of Blood & Cancer, is on location at the 2019 annual meeting of the American Society of Clinical Oncology during this podcast, speaking with Davendra Sohal, MD, of the Cleveland Clinic. Dr. Sohal presented preliminary results from SWOG S1505, a phase 2 study on neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, talks about what happens when a cancer patient wants to act against medical advice.
By Emily Bryer, DO, resident in the department of internal medicine, University of Pennsylvania, Philadelphia
SWOG S1505 trial: Neoadjuvant chemotherapy experience with mFOLFIRINOX vs. gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
- Patients with resectable pancreatic adenocarcinoma typically have surgery prior to chemotherapy.
- Many patients with pancreatic adenocarcinoma recur after surgery.
- Randomized phase 2 trial of resectable pancreatic adenocarcinoma
- Patients were given chemotherapy for 3 months. If there was no progression, patients underwent surgery, followed by more chemotherapy.
- About one-third of these patients were found to have nonresectable disease.
- Additional data will be published in 2020.
- Neoadjuvant chemotherapy may be easier to tolerate since it is given prior to surgery.
- Venous thromboembolism is a common among patients with metastatic pancreatic cancer.
SWOG S1505 trial: NCT02562716
ASCO 2019, Abstract 4137
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz